About Richard Meyer

Passionate, award-winning Marketing and Media Executive with an MBA and 15+ years success implementing cutting-edge strategies. Career highlights include driving development/launch of a groundbreaking e-Marketing branding initiative for Eli Lilly product Cialis that led to Website becoming #1 online pharma destination (and #1 in prescription conversions), increasing leads 30% and ROI 38% for $1B manufacturer Medtronic

Fake medical news threatens our lives

  • While misinformation has been the object of great attention in politics, medical misinformation might have an even greater body count.
  • False medical information can also lead to patients’ experiencing greater side effects through the “nocebo effect.”
  • Cancer is another big target for pushers of medical misinformation — many of whom are making money off alternative therapies.
  • Fake news represents a huge opportunity for pharma to lead the conversation.
Continue reading

Pharma companies lag in digital transformation

  • The life sciences industry’s commitment to digital transformation is increasing, but few organizations are digitally maturing.
  • Digital transformation is no longer a buzzword, but a strategic imperative for life sciences companies.
  • While first movers would likely gain a competitive advantage, all of today’s companies risk falling behind their competitors in delivering across all elements of the value chain if their strategies are limited to a few pilots and experiments.
  • Life sciences companies have been fast followers in adopting new technologies, but waiting too long to commit could leave some companies with portions of their value chains disrupted in an ever more price-conscious segment.
Continue reading

Pharma’s inexcusable pricing of insulin

  • A study showing that one in four insulin-treated patients surveyed at an urban US diabetes center were found to be cutting back on insulin use because of cost has been published.
  • The survey results also reveal that cost-related insulin underuse was associated with worse glycemic control and that more than a third of patients did not discuss the insulin underuse with their clinicians.
  • Of those who completed the survey, 25.5% (51) reported cost-related insulin underuse.
Continue reading